NO20025220L - Ny fremgangsmåte - Google Patents

Ny fremgangsmåte

Info

Publication number
NO20025220L
NO20025220L NO20025220A NO20025220A NO20025220L NO 20025220 L NO20025220 L NO 20025220L NO 20025220 A NO20025220 A NO 20025220A NO 20025220 A NO20025220 A NO 20025220A NO 20025220 L NO20025220 L NO 20025220L
Authority
NO
Norway
Prior art keywords
new procedure
stable
formoterol
copd
rhinitis
Prior art date
Application number
NO20025220A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025220D0 (no
Inventor
Eva Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20025220(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20025220L publication Critical patent/NO20025220L/no
Publication of NO20025220D0 publication Critical patent/NO20025220D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Separation By Low-Temperature Treatments (AREA)
NO20025220A 2000-05-19 2002-10-31 Ny fremgangsmÕte NO20025220D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012261.4A GB0012261D0 (en) 2000-05-19 2000-05-19 Novel process
PCT/SE2001/001117 WO2001089491A1 (en) 2000-05-19 2001-05-17 Novel process

Publications (2)

Publication Number Publication Date
NO20025220L true NO20025220L (no) 2002-10-31
NO20025220D0 NO20025220D0 (no) 2002-10-31

Family

ID=9892016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025220A NO20025220D0 (no) 2000-05-19 2002-10-31 Ny fremgangsmÕte

Country Status (19)

Country Link
US (3) US7179489B2 (es)
EP (1) EP1289505B1 (es)
JP (3) JP5739597B2 (es)
KR (1) KR100799452B1 (es)
CN (1) CN1245962C (es)
AT (1) ATE276748T1 (es)
AU (2) AU2001259006B2 (es)
BR (1) BRPI0110947B8 (es)
CA (1) CA2409660C (es)
DE (1) DE60105807T2 (es)
ES (1) ES2227190T3 (es)
GB (1) GB0012261D0 (es)
IL (2) IL152532A0 (es)
MX (1) MXPA02011310A (es)
NO (1) NO20025220D0 (es)
NZ (1) NZ522419A (es)
PT (1) PT1289505E (es)
WO (1) WO2001089491A1 (es)
ZA (1) ZA200208710B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
EP1572217B1 (en) 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
AU2004262902B2 (en) * 2003-07-29 2009-07-30 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
JP2008502699A (ja) * 2004-06-14 2008-01-31 セプラコール・インコーポレイテッド 肺疾患治療方法、及びそのための組成物
CN104177448A (zh) 2005-02-10 2014-12-03 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
PL2538922T3 (pl) * 2010-02-25 2016-11-30 Formułowanie kompozycji do leczenia stanów zapalnych
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
RU2019110128A (ru) * 2012-02-28 2019-05-08 Айсьютика Холдингз Инк. Бви Ингаляционные фармацевтические композиции
MX2022003427A (es) 2019-09-24 2022-04-18 Chiesi Farm Spa Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE59203732D1 (de) * 1991-07-01 1995-10-26 Gergely Gerhard Lutsch- oder Kautablette.
JPH0558911A (ja) * 1991-08-27 1993-03-09 N D Shinyaku Kaihatsu Kenkyusho:Kk 鎮咳去痰剤
PT613371E (pt) 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6034604A (en) * 1999-01-14 2000-03-07 Kaltner; George Deactivation prevention for electronic article surveillance systems
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
CN1429103A (zh) 2003-07-09
MXPA02011310A (es) 2003-04-25
EP1289505A1 (en) 2003-03-12
PT1289505E (pt) 2005-01-31
US7179489B2 (en) 2007-02-20
JP2003534272A (ja) 2003-11-18
JP2013040214A (ja) 2013-02-28
NZ522419A (en) 2003-08-29
KR20030001514A (ko) 2003-01-06
CN1245962C (zh) 2006-03-22
WO2001089491A1 (en) 2001-11-29
US20030129245A1 (en) 2003-07-10
IL152532A0 (en) 2003-06-24
KR100799452B1 (ko) 2008-01-30
EP1289505B1 (en) 2004-09-22
DE60105807T2 (de) 2005-11-24
AU5900601A (en) 2001-12-03
ZA200208710B (en) 2004-02-10
ATE276748T1 (de) 2004-10-15
IL219785A0 (en) 2012-06-28
CA2409660A1 (en) 2001-11-29
CA2409660C (en) 2011-02-08
AU2001259006B2 (en) 2005-03-24
US20100183729A1 (en) 2010-07-22
JP5739597B2 (ja) 2015-06-24
BR0110947A (pt) 2003-04-29
DE60105807D1 (de) 2004-10-28
BRPI0110947B8 (pt) 2021-05-25
IL219785A (en) 2015-10-29
US7670625B2 (en) 2010-03-02
US20070259048A1 (en) 2007-11-08
JP2015042693A (ja) 2015-03-05
BRPI0110947B1 (pt) 2016-12-27
NO20025220D0 (no) 2002-10-31
ES2227190T3 (es) 2005-04-01
GB0012261D0 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
NO20025220D0 (no) Ny fremgangsmÕte
IL152470A0 (en) Pharmaceutical composition comprising micronised formoterol and micronised glucocorticosteroid
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
ATE330585T2 (de) Behandlung von atemerkrankungen
SE0200356D0 (sv) Novel use
SE9900833D0 (sv) Novel combination
EA200500328A1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
SE9900834D0 (sv) Novel combination
MXPA04007294A (es) Composicion para inhalacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application